BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALN-VSP: Completed Phase I enrollment

Alnylam completed enrollment of over 40 patients in an open-label, dose-escalation Phase I trial evaluating 0.1-1.5 mg/kg IV ALN-VSP. The company developed ALN-VSP using Tekmira's stable nucleic acid-lipid particles (SNALP) technology.


Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >